Protalix BioTherapeutics Discounted Cash Flow

Protalix BioTherapeutics posts a DCF fair value of $-2.5. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Markets price PLX on many factors — sentiment, liquidity, and near-term news — while DCF focuses on long-run cash flows. The current fair-value estimate of $-2.5 sits 187.3% below the live price. Large gaps can highlight opportunity or model risk; the charts on this page help you see how the estimate has moved over time.

Context for PLX's DCF fair value usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Protalix BioTherapeutics's other metric pages and overview cover the third.

Judging Protalix BioTherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in DCF fair value easier to interpret. Start with $-2.5 here, then scan peer and history charts to see if the gap is persistent.